Αρχική World News FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer World News FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer Από Ogkologos - 29 Ιανουαρίου, 2026 452 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Woman Showed Up To Their Wedding And Stole All Their Gifts.... 11 Μαρτίου, 2019 Expressive Writing, What is It? 12 Μαΐου, 2021 Mouse Study Points to Strategy for Preserving Bone During Chemotherapy 25 Φεβρουαρίου, 2020 2021/22 in review: Charity looks to the future with ambitious new... 21 Ιουλίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α Sugar and cancer – what you need to know In Memory of Håkan Mellstedt: Former ESMO President Analyzing Tumor RNA May Help Match Patients with Most Effective Cancer...